Shear Wave Elastography of Pancreatic Adenocarcinoma Undergoing Chemotherapy with Adjuvant Sonoporation Treatment – Initial Results
Tuesday, April 9, 2024
9:02am – 9:09am
Location: 412
Authors: Priscilla Machado, Thomas Jefferson University Trang Vu, Thomas Jefferson University Hospital John Eisenbrey, Thomas Jefferson University James Posey III, Thomas Jefferson university Spiros Kotopoulis, University of Bergen Babar Bashir, Sidney Kimmel Cancer Center at Thomas Jefferson University Patrick Mille, TJUH Atrayee Basu Mallick, TJUH Daniel Lin, Thomas Jefferson University Hospital Ingrid Nordaas, Haukeland University Hospital Audun Trelsgård, Haukeland University Hospital Georg Dimcevski, Haukeland University Hospital, Bergen, Norway Odd Helge Gilja, Haukeland University Hospital Kirk Wallace, GE HealthCare Technology and Innovation Center Flemming Forsberg, Thomas Jefferson University Forsberg,
Sonoporation is a novel method that can enhance the therapeutic efficacy of co-administered chemotherapy by performing localized contrast-enhanced ultrasound (CEUS) imaging at the time of optimal chemotherapy concentration in the vascular system. An ongoing Phase II clinical trial aims to improve standard of care chemotherapy treatment by adding sonoporation. As part of this study, the tumor stiffness was assessed using shear wave elastography (SWE) during the sonoporation treatment. The objective of this study was to compare SWE measurements of tumor stiffness during sonoporation treatment in order differentiate responders from non-responders. This was an initial analysis of the comparison of SWE PDAC stiffness between responders and non-responders to standard of care chemotherapy treatment augmented with sonoporation. The mean values showed that for responders there was decrease in tumor stiffness from the first to the last cycle translating into a significant statistical difference (p = 0.005), whereas for non-responders there was statistically significant increase in tumor stiffness from the first to the last cycle (p = 0.001). The results also showed that between responders versus non-responders there was significant statistical difference for the first cycle (p = 0.001). These initial results suggest that PDAC stiffness may be used to indicate chemotherapy response.